Sanofi reports positive data from Phase III EoE treatment trial [Yahoo! Finance]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
The study is designed to evaluate the efficacy and safety of Dupixent in these children. A fully human monoclonal antibody, Dupixent targets the interleukin-4 (IL4) and interleukin-13 (IL13) pathways without being an immunosuppressant. The double-blind, randomised, placebo-controlled trial consisted of two parts. Part A involved 102 patients and tested Dupixent at a weight-tiered higher or lower dose against a placebo for 16 weeks. Part B was a 36-week extension where patients continued or switched to the appropriate Dupixent dose. Histologic remission at 16 weeks was the trial's primary endpoint, with secondary endpoints comprising endoscopic and histopathologic assessments and disease severity, clinical signs and symptoms of EoE. The results indicated that a higher proportion of patients on the weight-tiered higher dose of Dupixent saw significant improvements at week 16 compared to the placebo group. These findings supported the US Food and Drug Administration's Priori
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Maternal RSV Task Force Emphasizes the Immediate Opportunity to Protect All Infants in Canada from RSV Disease [Yahoo! Finance]Yahoo! Finance
- DRI Healthcare Trust Announces Acquisition of an Additional Royalty Interest in the Worldwide Sales of Xenpozyme® (olipudase alfa) for the Treatment of Acid Sphingomyelinase Deficiency [Yahoo! Finance]Yahoo! Finance
- Groupe Guillin And Two More Top Dividend Stocks On Euronext Paris [Yahoo! Finance]Yahoo! Finance
- DSV, CVC Seen as Lead Contenders for Schenker After Maersk Drops [BNN Bloomberg (Canada)]BNN Bloomberg
- DSV, CVC Seen as Lead Contenders for Schenker After Maersk Drops [Yahoo! Finance]Yahoo! Finance
SNY
Sec Filings
- 6/28/24 - Form 11-K
- 6/28/24 - Form 11-K
- 6/11/24 - Form 6-K
- SNY's page on the SEC website